Jiang J, Wang Q, Wu Q, Deng B, Guo C, Chen J
Front Pharmacol. 2025; 16:1523713.
PMID: 39963244
PMC: 11830817.
DOI: 10.3389/fphar.2025.1523713.
Hassall J, Coxon C, Patel V, Goldenberg S, Sergaki C
NPJ Antimicrob Resist. 2025; 2(1):16.
PMID: 39843577
PMC: 11721362.
DOI: 10.1038/s44259-024-00033-8.
Alshehri F, Alorfi N
Front Pharmacol. 2023; 14:1130670.
PMID: 36825158
PMC: 9941161.
DOI: 10.3389/fphar.2023.1130670.
Yoon Y, Moon C, Kim J, Heo S, Lee M, Lee S
Infect Chemother. 2023; 54(4):812-853.
PMID: 36596690
PMC: 9840951.
DOI: 10.3947/ic.2022.0156.
Nguyen L, Lo T, La H, Doan H, Le N
Hepat Med. 2022; 14:101-109.
PMID: 35936811
PMC: 9348134.
DOI: 10.2147/HMER.S369966.
Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway.
Maini A, Becares N, China L, Tittanegro T, Patel A, De Maeyer R
JHEP Rep. 2021; 3(6):100332.
PMID: 34825153
PMC: 8603213.
DOI: 10.1016/j.jhepr.2021.100332.
Bacterial Pathogens, Drug-Resistance Profile and Its Associated Factors from Patients with Suspected Peritonitis in Southern Ethiopia.
Alelign D, Ameya G, Siraj M
Infect Drug Resist. 2021; 14:4107-4117.
PMID: 34675556
PMC: 8502028.
DOI: 10.2147/IDR.S335103.
Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-Producing in Patients with Liver Cirrhosis.
Chen W, Hung C, Chen Y, Cheng J, Shin-Jung Lee S, Tseng F
Pathogens. 2021; 10(1).
PMID: 33466521
PMC: 7824895.
DOI: 10.3390/pathogens10010037.
Emerging Gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective study.
Guo J, Shi J, Wang H, Chen H, Liu S, Li J
Exp Ther Med. 2019; 17(6):4568-4576.
PMID: 31186679
PMC: 6507503.
DOI: 10.3892/etm.2019.7502.
Epidemiology and risk factors for multi-drug resistant hospital-acquired urinary tract infection in patients with liver cirrhosis: single center experience in Serbia.
Milovanovic T, Dumic I, Velickovic J, Stojkovic Lalosevic M, Nikolic V, Palibrk I
BMC Infect Dis. 2019; 19(1):141.
PMID: 30755176
PMC: 6373165.
DOI: 10.1186/s12879-019-3761-5.
Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies.
Marciano S, Diaz J, Dirchwolf M, Gadano A
Hepat Med. 2019; 11:13-22.
PMID: 30666172
PMC: 6336019.
DOI: 10.2147/HMER.S164250.
Bloodstream infection due to in liver cirrhosis patients: clinical features and outcomes.
Tu B, Bi J, Wu D, Zhao P, Shi L, Xie Y
Oncotarget. 2018; 9(87):35780-35789.
PMID: 30515269
PMC: 6254670.
DOI: 10.18632/oncotarget.23200.
Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review.
Shizuma T
World J Hepatol. 2018; 10(2):254-266.
PMID: 29527261
PMC: 5838444.
DOI: 10.4254/wjh.v10.i2.254.
Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection.
Xie Y, Tu B, Zhang X, Bi J, Shi L, Zhao P
Oncotarget. 2018; 9(3):3980-3995.
PMID: 29423099
PMC: 5790516.
DOI: 10.18632/oncotarget.23582.
Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis.
Fiore M, Maraolo A, Gentile I, Borgia G, Leone S, Sansone P
World J Hepatol. 2017; 9(30):1166-1175.
PMID: 29109849
PMC: 5666303.
DOI: 10.4254/wjh.v9.i30.1166.
Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review.
Fiore M, Maraolo A, Gentile I, Borgia G, Leone S, Sansone P
World J Gastroenterol. 2017; 23(25):4654-4660.
PMID: 28740354
PMC: 5504381.
DOI: 10.3748/wjg.v23.i25.4654.